Compositions and methods for treating pulmonary fibrosis
AssigneesArizona Board of Regents on Behalf of the University of Arizona, The United States of America as represented by the Department of Veterans Affairs
InventorsJoe G.N. Garcia, Louise Hecker
Life of this patent
Estimating the term…
Abstract
Inhibition of the expression and/or function of nicotinamide phosphoribosyltransferase (NAMPT) can reduce, prevent or reverse the pathophysiological vascular changes associated with the onset and progression of Pulmonary Fibrosis. Compositions and methods to inhibit the expression and function of NAMPT for treating and preventing Pulmonary Fibrosis in a subject in need are provided. The compositions and methods are useful for the modulation of pathophysiological processes that contribute to the development and progression of Pulmonary Fibrosis by reducing lung inflammation, aberrant myofibroblast accumulation and deposition of collagen in fibrotic foci.
Claims29
A composition to treat Pulmonary Fibrosis (PF) in a subject in need thereof comprising one or more inhibitors of nicotinamide phosphoribosyltransferase (NAMPT), or one or more inhibitors of a NAMPT receptor, or combinations thereof, and, optionally, a pharmaceutically acceptable excipient for administration into the body.
Dependencies are inferred from the claim text.